Glenmark Pharma in Focus: GST Search Operations & Strong Q3 Results
Market
C
CNBC TV18•01-02-2026, 04:05
Glenmark Pharma in Focus: GST Search Operations & Strong Q3 Results
- •Glenmark Pharma shares are under scrutiny following a GST search and seizure operation conducted at its Mumbai offices from January 27-31, 2026.
- •The company reported a 15.1% year-on-year revenue growth to ₹3,900.6 crore for the December quarter.
- •EBITDA surged by 44.9% to ₹869.7 crore, with EBITDA margin expanding to 22.3% from 17.7% in the previous year.
- •Both India and North America businesses showed robust growth, increasing by 22% and 24% respectively, with North America aided by ISB 2001 licensing income.
- •Glenmark stated that it cooperated fully with GST authorities, provided all requested documents, and confirmed no material impact on its financials or operations.
Why It Matters: Glenmark Pharma faces GST scrutiny but reports strong Q3 growth driven by India and North America markets.
✦
More like this
Loading more articles...
